methyprylon (noludar) Report issue

Small molecule Approved FDA
ChEMBL DrugBank Drug Central Drugs@FDA KEGG MeSH PubChem repoDB

Active Ingredient History

NOW
  • Now
Methyprylon (brand name Noludar) is a sedative agent, which used to treat insomnia. But then the drug was replaced in the market by another drugs with less side effects. The precise mechanism of action is not known, but was made suggestion, that methyprylon increases the effects of gamma-aminobutyric acid (GABA), an inhibitory neurotransmitter in the brain.   NCATS

Chemistry

  • SMILES: CCC1(CC)C(=O)NCC(C)C1=O
  • InChIKey: SIDLZWOQUZRBRU-UHFFFAOYSA-N
  • Mol. Mass: 183.2475
  • ALogP: 1.13
  • ChEMBL Molecule:
    methyprylon  
More Chemistry

Pharmacology

Alternative names

2,4-piperidinedione, 3,3-diethyl-5-methyl- | dimerin | methprylon | methyprolon | methyprylon | methyprylone | methyprylonum | metiprilon | metiprilona | metiprilone | noctan | noludar

Organizations (1)

Research & Development (0)

Organization Org Type FDA approvals Clinical Trials involvement Org ID Force Sort

Marketing (1)

Organization Org Type FDA approvals Clinical Trials involvement Org ID Force Sort

Indications (1)

Approved Indications (1)


 

Sleep Initiation and Maintenance Disorders

Experimental Indications - Clinical Trial Phases 1-4 (0)

Feedback

Data collection and curation is an ongoing process for CDEK - if you notice any information here to be missing or incorrect, please let us know! When possible, please include a source URL (we verify all data prior to inclusion).

Report issue